Delving into the Latest Updates on Adrenas Therapeutics, Inc. with Synapse

概览

关联

1

项与 Adrenas Therapeutics, Inc. 相关的药物

BBP-631

靶点

CYP21A2

作用机制

CYP21A2基因转移

在研机构-

原研机构

Life Technologies, Inc.

在研适应症-

非在研适应症

先天性肾上腺增生

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

2

项与 Adrenas Therapeutics, Inc. 相关的临床试验

NCT04783181

/ Active, not recruiting临床1/2期

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Gene Therapy for Congenital Adrenal Hyperplasia Through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene

This study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.

开始日期2021-07-01

申办/合作机构

Adrenas Therapeutics, Inc.

NCT05101902

/ CompletedN/A

Pre-screening Study to Identify Adult Participants with Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Who May Be Eligible for Treatment in the CAH-301 Trial with BBP-631, an Adeno-associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene

This pre-screening study is designed to determine potential eligibility of adults with classic CAH due to 21-hydroxylase deficiency (21-OHD) for participation in the CAH-301 [NCT04783181] gene therapy trial with BBP-631.

开始日期2021-07-01

申办/合作机构

Adrenas Therapeutics, Inc.

100 项与 Adrenas Therapeutics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Adrenas Therapeutics, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Adrenas Therapeutics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Adrenas Therapeutics, Inc. 相关的转化医学

登录后查看更多信息